Cardiol Therapeutics (TSE:CRDL) Stock Price Down 3.3% - Should You Sell?

Key Points

• Cardiol Therapeutics Inc. stock price decreased by 3.3% to C$1.45, with a trading volume that rose by 34% from average levels.
• The company has a market capitalization of C$121.41 million and negative PE ratio of -3.02, indicating potential challenges in profitability.
• Cardiol is focused on developing therapies for heart disease, with its lead drug candidate being CardiolRxTM, which is currently in clinical development.

Cardiol Therapeutics Inc. (TSE:CRDL - )'s stock price was down 3.3% during trading on Thursday . The company traded as low as C$1.45 and last traded at C$1.45. Approximately 137,765 shares changed hands during mid-day trading, an increase of 34% from the average daily volume of 102,813 shares. The stock had previously closed at C$1.50.

Cardiol Therapeutics Stock Performance

The stock's 50-day simple moving average is C$1.61 and its 200 day simple moving average is C$1.63. The company has a debt-to-equity ratio of 1.59, a quick ratio of 6.84 and a current ratio of 2.49. The company has a market capitalization of C$121.41 million, a PE ratio of -3.02 and a beta of 0.95.

About Cardiol Therapeutics

Cardiol Therapeutics Inc NASDAQ: CRDL TSX: CRDL is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead drug candidate, CardiolRxTM (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.